Skip to main content

Table 1 Demographic, disease, and treatment characteristics

From: Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy

Characteristic Lymph node positive (n = 58) Lymph node negative (n = 78) P-value
Median age at diagnosis (range), yrs 66.7 (50.9 – 76.8) 67.4 (48.3 – 79.1) 0.03
Mode of detection, n (%)    0.17
 Symptomatic 25 (43) 25 (32)  
 Screening 33 (57) 53 (68)
Median PSA (range), ng/mL 24.4 (1.8 – 109.0) 26.0 (2.9 – 109.0) 0.26
Gleason sum, n (%)    0.21
 3 + 3 3 (5) 1 (1)
 3 + 4 10 (17) 8 (10)
 4 + 3 13 (22) 22 (28)
 4 + 4 23 (40) 29 (37)
 4 + 5 5 (9) 16 (21)
 5 + 4 3 (5) 2 (3)
 5 + 5 1 (2) 0 (0)
Clinical stage, n (%)    0.58
 T1b 1 (2) 0 (0)
 T1c 1 (2) 6 (8)
 T2a 3 (3) 1 (1)
 T2b 3 (5) 4 (5)
 T2c 3 (5) 3 (4)
 T3a 23 (40) 32 (41)
 T3b 23 (40) 30 (38)
 T4 1 (2) 2 (3)
Median duration of ADT (range), months 40.3 (11.9 – 54.4) 28.7 (9.0 – 60.2) <0.001
  1. Abbreviations: prostate-specific antigen (PSA)